The Global Market for Stem Cell Exosome Therapeutic was valued at US$ xx Mn in 2019 and it is expected to reach US$ xx million in 2030, recording a promising CAGR of 16% during the period of 2020-2030. Exosomes are gaining popularity rapidly as a method to access the therapeutic benefits of stem cells without the complications and difficulties of delivering the cells to patients. Exosomes are sold as diagnostic devices, therapeutic agents, cosmeceuticals, research tools, and much more. The increasing prevalence of autoimmune disease, chronic inflammation, lyme disease, and other chronic degenerative diseases is expected to boost the demand for stem cell exosome therapeutic. Additionally, the emerging research activities in exosome therapeutics are likely to accelerate the market growth in upcoming years. In the last few years, the technologies related to exosomes have been mainly developed and the demand for these technologies are very useful the fields of precision medicine, liquid biopsy, and regenerative medicine. Therefore, this is further projected to enhance the adoption of stem cell exosome therapeutic. Moreover, advancements in exosome isolation and purification techniques and rising healthcare infrastructure are likely to offer lucrative growth opportunities to the global stem cell exosome therapeutic in the next few years.
The Stem Cell Exosome Therapeutics Market is a segment based on source type, application, and geography. In terms of source type, the global market is segregated into MSC, dendritic cells, umbilical MSC, plasma, and others. In 2019, the MSC or mesenchymal stem cells segment accounted for a significant share of the global stem cell exosome therapeutics market. Mesenchymal stem cells (MSCs) are one of the most commonly employed cell types as a cell-based therapy for treating human diseases. Mesenchymal stem cells are multipotent, self-renewable, easily manageable, and customarily stretchy in vitro with exceptional genomic stability. It is widely used in the treatment of degenerative and inflammatory disease offspring cells encompassing the transgene after transplantation. Mesenchymal stem cells are used to repair injured organs such as the lung, heart, and kidney. Moreover, the dendritic cells segment is anticipated to grow at the highest CAGR during the forecast period. Based on the application, the market is segmented into precision medicine, regenerative medicine, and others. Regenerative medicine is the largest contributing category to the global stem cell exosome therapeutic market. Regenerative medicine seeks to enhance the regeneration of tissue and organs that are damaged, malfunctioning and incomplete. Stem cell therapies are promising therapeutics in this field in damaged organs such as the myocardium after heart infarction, spinal cord injury, stroke, damaged liver, and retina diseases. Mesenchymal stem cells represent a promising stem cell population for applications in regenerative medicine. Moreover, stem cell exosome therapeutic has potential applications in precision medicine.
Geographically, the global stem cell exosome therapeutic market has been segmented into North America, Asia Pacific, Latin America, Europe, and Middle East & Africa. North America dominates the global stem cell exosome therapeutic market due to the increasing number of autoimmune diseases. Additionally, the emerging research activities required for exosome therapeutics are also projected to boost the market growth. Moreover, the U.S. dominated the regional market owing to the rising preventive expenditure for healthcare and the presence of leading manufacturers of stem cell exosome therapeutics. Europe is anticipated to be the second-largest market for stem cell exosome therapeutic due to the developed healthcare sectors. Furthermore, the Asia Pacific is expected to grow at the highest CAGR with the improved healthcare services, especially in the emerging economies of Asia Pacific. Some of the market players leading the global stem cell exosome therapeutic market include Direct Biologics, MDimune Inc., ExoCoBio, Exopharm Pty Ltd, Invitrx Inc., OmniSpirant Limited, RoosterBio Inc., Stemcell Medicine Ltd., VivaZome Therapeutics Pty Ltd, Evox Therapeutics, Kimera Labs, The Cell-Factory BVBA (Esperite), Capricor Therapeutics, Inc., Unicyte AG, Exogenus Therapeutics, Everkine Corporation, Creative Medical Technology Holdings, Anjarium Biosciences, ReNeuron, Stem Cell Medicine Ltd., and Codiak Biosciences Key players of stem cell exosome therapeutics are primarily focusing on product innovation, joint ventures, regional expansion, and investment in research and development. For instance, Stem Cells Group has recently announced the expansion of its new stem cell offices in Cochabamba, Bolivia and Valencia, Spain.